{"id":"tobramycin-and-dexamethasone-ophthalmic-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Conjunctival erythema"},{"rate":null,"effect":"Lid edema"},{"rate":null,"effect":"Transient blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and prevents protein synthesis, effectively killing susceptible gram-negative and gram-positive bacteria. Dexamethasone is a potent corticosteroid that suppresses inflammatory mediators and immune cell activity, reducing swelling, redness, and discomfort. Together, they provide both antimicrobial and anti-inflammatory effects for ocular infections and inflammation.","oneSentence":"Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:05.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial keratitis"},{"name":"Ocular inflammation associated with bacterial infection"}]},"trialDetails":[{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":"Cataract, Pseudoexfoliation Syndrome","enrollment":62},{"nctId":"NCT02873806","phase":"PHASE4","title":"Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2013-03","conditions":"Open-angle Glaucoma","enrollment":53},{"nctId":"NCT03739528","phase":"PHASE3","title":"Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery","status":"COMPLETED","sponsor":"NTC srl","startDate":"2018-09-03","conditions":"Cataract","enrollment":808},{"nctId":"NCT03975374","phase":"EARLY_PHASE1","title":"To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension","status":"UNKNOWN","sponsor":"Sutphin Drugs","startDate":"2019-06-15","conditions":"Blepharo Conjunctivitis","enrollment":5000},{"nctId":"NCT01102244","phase":"PHASE3","title":"A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-04","conditions":"Blepharitis","enrollment":122},{"nctId":"NCT00362895","phase":"PHASE3","title":"A Bioequivalence Study of Tobradex AF","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04","conditions":"Cataract","enrollment":995},{"nctId":"NCT01028027","phase":"PHASE3","title":"Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-10","conditions":"Conjunctivitis, Keratitis, Blepharitis","enrollment":357},{"nctId":"NCT00447577","phase":"PHASE4","title":"Zylet vs TobraDex in Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-01","conditions":"Blepharokeratoconjunctivitis","enrollment":276},{"nctId":"NCT00532961","phase":"PHASE4","title":"Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-02","conditions":"Inflammation","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tobramycin and dexamethasone ophthalmic suspension","genericName":"Tobramycin and dexamethasone ophthalmic suspension","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye. Used for Bacterial conjunctivitis, Bacterial keratitis, Ocular inflammation associated with bacterial infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}